Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study

Overview of attention for article published in Trials, October 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

blogs: 1 blog

twitter: 27 tweeters

Citations

dimensions_citation: 24 Dimensions

Readers on

mendeley: 63 Mendeley
citeulike: 1 CiteULike

Summary Blogs Twitter Dimensions citations

So far, Altmetric has seen 30 tweets from 27 users, with an upper bound of 152,269 followers.

RT @jsross119: Erick's paper demonstrates. Reporting biases are diminished for newer vs older antidepressants! Bonus content, (ICYMI) we've…

19 Jan 2022

Reply Retweet Favourite

Erick's paper demonstrates. Reporting biases are diminished for newer vs older antidepressants! Bonus content, (ICYMI) we've also examined FDAAA's impact for various drug classes & medical devices (2/2) https://t.co/kG4u5QAgbN, https://t.co/TCCmbksQ2C,

19 Jan 2022

Reply Retweet Favourite

We had previously shown that FDAAA was associated with higher rates of trial registration and results reporting on https://t.co/ickEwc8kA2 and significantly lower degrees of publication bias for drug trials (2/5) https://t.co/5dpAXjVVN7 and https://t.co/TC

18 Nov 2021

Reply Retweet Favourite

RT @AllenFrancesMD: Very Good News: New study shows #pharma is now less able to hype positive results & hide negative studies. https://t.co…

13 Nov 2018

Reply Retweet Favourite

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity, including 26 additional tweets.